Unknown

Dataset Information

0

Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy.


ABSTRACT: Anti-programmed cell death 1 ligand 1 (PD-L1) therapy is extraordinarily effective in select patients with cancer. However, insufficient lymphocytic infiltration, weak T cell-induced inflammation, and immunosuppressive cell accumulation in the tumor microenvironment (TME) may greatly diminish the efficacy. Here, we report development of the FX@HP nanocomplex composed of fluorinated polymerized CXCR4 antagonism (FX) and paclitaxel-loaded human serum albumin (HP) for pulmonary delivery of anti-PD-L1 small interfering RNA (siPD-L1) to treat orthotopic lung tumors. FX@HP induced T cell infiltration, increased expression of calreticulin on tumor cells, and reduced the myeloid-derived suppressor cells/regulatory T cells in the TME, thereby acting synergistically with siPD-L1 for effective immunotherapy. Our work suggests that the CXCR4-inhibiting nanocomplex decreases tumor fibrosis, facilitates T cell infiltration and relieves immunosuppression to modulate the immune process to improve the objective response rate of anti-PD-L1 immunotherapy.

SUBMITTER: Li Z 

PROVIDER: S-EPMC7228744 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy.

Li Zhaoting Z   Wang Yixin Y   Shen Yuexin Y   Qian Chenggen C   Oupicky David D   Sun Minjie M  

Science advances 20200515 20


Anti-programmed cell death 1 ligand 1 (PD-L1) therapy is extraordinarily effective in select patients with cancer. However, insufficient lymphocytic infiltration, weak T cell-induced inflammation, and immunosuppressive cell accumulation in the tumor microenvironment (TME) may greatly diminish the efficacy. Here, we report development of the FX@HP nanocomplex composed of fluorinated polymerized CXCR4 antagonism (FX) and paclitaxel-loaded human serum albumin (HP) for pulmonary delivery of anti-PD-  ...[more]

Similar Datasets

| S-EPMC6819555 | biostudies-literature
| S-EPMC5873884 | biostudies-other
| S-EPMC9909878 | biostudies-literature
| S-EPMC10055616 | biostudies-literature
| S-EPMC7851350 | biostudies-literature
| S-EPMC9594910 | biostudies-literature
| S-EPMC7497526 | biostudies-literature
| S-EPMC9113929 | biostudies-literature
| S-EPMC9251065 | biostudies-literature
| S-EPMC10373067 | biostudies-literature